BNF for Children 2011-2012 (British National Formulary)

                                                      BNF for Children 2011-2012 (British National Formulary)

BNF for Children 2011-2012 aims to provide prescribers, pharma-cists, and other healthcare professionals with sound up-to-date information on the use of medicines for treating children.

How BNF for Children is constructed

BNF for Children (BNFC) is unique in bringing together authoritative, independent guidance on best practice with clinically validated drug information, enabling healthcare professionals to select safe and effective medicines for individual children.

Information in BNFC has been validated against emer-ging evidence, best-practice guidelines, and advice from a network of clinical experts. BNFC includes a great deal of advice that goes beyond marketing authorisations (product licences or summaries of product characteris-tics). This is necessary because licensed indications frequently do not cover the clinical needs of children; in some cases, products for use in children need to be specially manufactured or imported. Careful considera-tion has been given to establishing the clinical need for unlicensed interventions with respect to the evidence and experience of their safety and efficacy.

Hundreds of changes are made between editions, and the most clinically significant changes are listed at the front of each edition.

Paediatric Formulary Committee

BNF for Children 2011-2012 (British National Formulary)

The Paediatric Formulary Committee (PFC) is respon-sible for the content of BNFC. The PFC includes a neonatologist and paediatricians appointed by the Royal College of Paediatrics and Child Health, paed-iatric pharmacists appointed by the Royal Pharmaceut-ical Society of Great Britain and the Neonatal and Paediatric Pharmacists Group, doctors appointed by the BMJ Publishing Group, a GP appointed by the Royal College of General Practitioners, and representa-tives from the Medicines and Healthcare products Reg-ulatory Agency (MHRA) and the UK health depart-ments. The PFC decides on matters of policy and reviews amendments to BNFC in the light of new evidence and expert advice. The Committee meets every 6 months and each member also receives proofs of all BNFC chapters for review before publication.

Dental Advisory Group

The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the group includes representatives from the British Dental Association.

Editorial team

BNFC staff editors are pharmacists with a sound under-standing of how drugs are used in clinical practice, including paediatrics. Each staff editor is responsible for editing, maintaining, and updating specific chapters of BNFC. During the publication cycle the staff editors review information in BNFC against a variety of sources (see below).

Amendments to the text are drafted when the editors are satisfied that any new information is reliable and relevant. The draft amendments are passed to expert advisers for comment and then presented to the Paed-iatric Formulary Committee for consideration. Addition-ally, for each edition, sections are chosen from every chapter for thorough review. These planned reviews aim to verify all the information in the selected sections and to draft any amendments to reflect current best prac-tice.

Staff editors prepare the text for publication and under-take a number of checks on the knowledge at various stages of the production.


Click on following Download: